Results 21 to 30 of about 49,826 (161)
Sodium-Glucose Co-Transporter 2 Inhibitors and Fracture Risk [PDF]
Diabetes Therapy, 2019 Patients with type 2 diabetes mellitus (T2DM) appear to have increased risk for fractures. In this context, the finding that canagliflozin, a sodium-glucose co-transporter-2 (SGLT) inhibitor, increased the risk for fracture compared with placebo in the Canagliflozin Cardiovascular Assessment Study (CANVAS), a large randomized controlled trial (RCT) in ...
Anastasia Erythropoulou-Kaltsidou +2 more
openaire +2 more sources
Sodium glucose co-transport 2 inhibitors for gout treatment
Discoveries, 2022 Hyperuricemia remains the most prevalent cause of gout. Gout patients present with joint inflammation and uric acid crystals deposition manifesting as tophi. The association of gout with increased risk of insulin resistance, diabetes, metabolic disorders, increased cardiometabolic risk, and kidney disease is well established.
Somagutta, Manoj Kumar Reddy +9 more
openaire +2 more sources
Лечащий Врач, 2022 Impaired kidney function has a negative impact on the course of heart failure in both patients with and without diabetes mellitus. Therefore, the development and study of the effectiveness of methods for the treatment of chronic heart failure, especially
E. V. Kovalenko +2 more
doaj +1 more source
IJU Case Reports, 2019 Introduction Sodium glucose co‐transporter 2 inhibitors constitute a new class of antidiabetic medication. Sodium glucose co‐transporter 2 inhibitors have been shown to exert anticancer effects.
Keita Izumi +4 more
doaj +1 more source
International Journal of Nephrology and Renovascular Disease, 2023 Rey Isidto,1 Romina Danguilan,2 Oscar Naidas,3 Russell Vilanueva,2 Mel-Hatra Arakama,2 Layla Marie Paraiso2 1HealthLink Medical, Surgical, Dental Clinics and Diagnostic Center, Iloilo City, Iloilo, Philippines; 2Department of Adult Nephrology, National ...
Isidto R +5 more
doaj
Cardiology Journal, 2023 Several mechanisms have been suggested to explain positive cardiovascular effects observed in studies with sodium-glucose co-transporter 2 (SGLT2) inhibitors.
Jacek Kubica +24 more
doaj +1 more source
Impact of SGLT2 inhibitors treatment on the chronic kidney disease in people with type 2 diabetes
Journal of Education, Health and Sport, 2022 Diabetes is the most common cause of CKD (chronic kidney disease). CKD is also one of the most important diabetic complication. SGLT2 (sodium glucose co‐transporter‐2) inhibitors are new class of medication used to lower high blood glucose level in ...
Marcin Czarkowski +3 more
doaj +1 more source
A case report of euglycemic ketoacidosis due to dapagliflozin treatment
Turkish Journal of Internal Medicine, 2021 Diabetic ketoacidosis (DKA) is a leading cause of mortality and morbidity in type 2 diabetic patients. Sodium-glucose co-transporter (SGLT-2) inhibitors are a new antidiabetic treatment class that increases the renal excretion of glucose.
Murat Çalapkulu +4 more
doaj +1 more source
A cell-based fluorescent glucose transporter assay for SGLT2 inhibitor discovery
Acta Pharmaceutica Sinica B, 2013 The sodium/glucose cotransporter 2 (SGLT2) is responsible for the majority of glucose reabsorption in the kidney, and currently, SGLT2 inhibitors are considered as promising hypoglycemic agents for the treatment of type 2 diabetes mellitus.
Yi Huan +4 more
doaj +1 more source
Severe intoxication caused by sodium-glucose cotransporter 2 inhibitor overdose: a case report
BMC Pharmacology and Toxicology, 2020 Background Sodium-glucose cotransporter 2 (SGLT2) inhibitors inhibit SGLT2, which is expressed in the proximal renal tubule, and thus reduce blood glucose levels by enabling the urinary excretion of excess glucose.
Miho Nakamura +4 more
doaj +1 more source